ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more
ANTENGENE CORP. DL-0001 (722) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ANTENGENE CORP. DL-0001 (722) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ANTENGENE CORP. DL-0001 - Net Assets Trend (None–None)
This chart illustrates how ANTENGENE CORP. DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ANTENGENE CORP. DL-0001 (None–None)
The table below shows the annual net assets of ANTENGENE CORP. DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ANTENGENE CORP. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ANTENGENE CORP. DL-0001 Competitors by Market Cap
The table below lists competitors of ANTENGENE CORP. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KRN Heat Exchanger and Refrigeration
NSE:KRN
|
$164.46 Million |
|
Shivalik Bimetal Controls Limited
NSE:SBCL
|
$164.48 Million |
|
LPKF Laser & Electronics AG
PINK:LPKFF
|
$164.49 Million |
|
Yem Chio Co Ltd
TW:4306
|
$164.53 Million |
|
Sunlour Pigment CO.LTD.
SHE:301036
|
$164.40 Million |
|
Sparebank 1 Ostfold Akershus
OL:SOAG
|
$164.37 Million |
|
QPOWER
NSE:QPOWER
|
$164.36 Million |
|
Energa SA
F:EN2
|
$164.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ANTENGENE CORP. DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ANTENGENE CORP. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ANTENGENE CORP. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ANTENGENE CORP. DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ANTENGENE CORP. DL-0001 (722) | €- | N/A | N/A | $164.44 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |